Real-World Effectiveness and Safety of Inclisiran Monotherapy in Chinese Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia
Research in Clinical Pharmacy · 30.06.2026 · 4 (1) · 24-33
DOI: 10.59931/rcp.26.0005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research in Clinical Pharmacy, erschienen am 30.06.2026. Verfasst von Xiao-Ya Li und 10 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BYNC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Li, X., Yang, M., Guo, Y., Mou, J., Tao, H., Soon, A., Zhou, Q., Shi, C., Li, Z., Zhang, Q., & Zhang, H. (2026). Real-World Effectiveness and Safety of Inclisiran Monotherapy in Chinese Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia. Research in Clinical Pharmacy, 4(1), 24-33. https://doi.org/10.59931/rcp.26.0005
Vancouver
Li X, Yang M, Guo Y, Mou J, Tao H, Soon A, et al. Real-World Effectiveness and Safety of Inclisiran Monotherapy in Chinese Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia. Research in Clinical Pharmacy. 2026;4(1):24-33. doi:10.59931/rcp.26.0005
BibTeX
@article{Li2026,
author = {Li, Xiao-Ya and Yang, Ming-Yao and Guo, Yu and Mou, Jin-Jin and Tao, Hua and Soon, Aaron and Zhou, Qin-Qin and Shi, Chen-Jie and Li, Zhen and Zhang, Qi and Zhang, Helen},
title = {Real-World Effectiveness and Safety of Inclisiran Monotherapy in Chinese Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia},
journal = {Research in Clinical Pharmacy},
year = {2026},
volume = {4},
number = {1},
pages = {24--33},
doi = {10.59931/rcp.26.0005}
}
EUVIMED